en · de · es · fr · pt
tb-500-notes.peptides4962.com › Wiki › Identification And Molecular Background — Explained

Identification And Molecular Background — Explained

By Editorial Desk · published 2025-12-19 · last reviewed 2026-01-02 · Wiki

This is a working overview of LKKTETQ, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-01-02. Anything still debated is marked as such rather than presented as settled.

Identification and Molecular Background

Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.

TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.

TB-500 Identity and Naming Background

Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.

Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.

Tb-500 at a glance

PropertyValueNotes
Generic designationSynthetic thymosin beta-4 N-terminal fragmentPeptide nomenclature varies by supplier
Peptide lengthApproximately 17 amino acid residuesReported length sometimes differs between sources
N-terminal modificationAcetyl groupAffects mass and chromatographic behaviour
Compound classSmall synthetic peptideNot a small-molecule drug
Common synonymsTB4 fragment; thymosin beta-4 fragmentNaming is inconsistent in popular media

Research Framing and Evidence Base

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Related pages on this site

Identity and Reported Background

Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.

Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.

TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Handling, Storage and Analytical Checks

Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.

Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.

Reference notes

Acecarbromal (INN) (brand names Sedamyl, Abasin, Carbased, Paxarel, Sedacetyl, numerous others), also known as acetylcarbromal and acetyladalin, is a hypnotic and sedative drug of the ureide (acylurea) group discovered by Bayer in 1917 that was formerly marketed in the United States and Europe. It is also used in combination with extract of quebracho and vitamin E as a treatment for erectile dysfunction under the brand name Afrodor in Europe. Acecarbromal is structurally related to the barbiturates, which are basically cyclized ureas. Prolonged use is not recommended as it can cause bromine poisoning.

=== Upgrades === Chain Home was the primary radar system of the UK for only a short time. By 1942, many of its duties had been taken over by the far more advanced AMES Type 7 ground-controlled interception (GCI) radar systems. Whereas CH scanned an area perhaps 100 degrees wide and required considerable effort to take measurements, the Type 7 scanned the entire 360-degree area around the station, and presented it on a plan position indicator, essentially a real-time two-dimensional map of the airspace around the station. Both fighters and bombers appeared on the display, and could be distinguished using Identification friend or foe (IFF) signals. The data from this display could be read directly to the intercepting pilots, without the need for additional operators or control centres. With the deployment of GCI, CH became the early warning portion of the radar network. To further simplify operations and reduce manpower requirements, the job of plotting the targets became semi-automated. An analogue computer of some complexity, known as "The Fruit Machine", was fed information directly from the operator console, reading the goniometer setting for bearing, and the range from the setting of a dial that moved a mechanical pointer along the screen until it lay over a selected target. When a button was pushed, the Fruit Machine read the inputs and calculated the X and Y location of the target, which a single operator could then plot on a map, or relay directly over the telephone.

My book The Sun, the Genome, and the Internet (1999) describes a vision of green technology enriching villages all over the world and halting the migration from villages to megacities. The three components of the vision are all essential: the sun to provide energy where it is needed, the genome to provide plants that can convert sunlight into chemical fuels cheaply and efficiently, the Internet to end the intellectual and economic isolation of rural populations. With all three components in place, every village in Africa could enjoy its fair share of the blessings of civilization. Dyson coined the term "green technologies", based on biology instead of physics or chemistry, to describe new species of microorganisms and plants designed to meet human needs. He argued that such technologies would be based on solar power rather than the fossil fuels whose use he saw as part of what he calls "gray technologies" of industry. He believed that genetically engineered crops, which he described as green, can help end rural poverty, with a movement based in ethics to end the inequitable distribution of wealth on the planet.

===== MeSH D08.811.913.200 – aldehyde-ketone transferases (EC 2.2) ===== MeSH D08.811.913.200.324 – acetolactate synthase MeSH D08.811.913.200.650 – transaldolase MeSH D08.811.913.200.825 – transketolase

Sources: en.wikipedia.org

Notes from published material

=== Hopman Cup === Zverev represented Germany at the Hopman Cup for four consecutive years from 2016 through 2019 with three different partners. In 2016, he competed with Sabine Lisicki. The duo won their tie against the French team, with Zverev winning both his singles and mixed doubles matches. However, they were shut out against Great Britain and Australia Green and did not advance to the final. The following year, he entered the competition with Andrea Petkovic. While the pair only won their tie against Great Britain, Zverev also defeated Federer in singles in his first tournament back from injury. Zverev enjoyed more success in 2018 and 2019, pairing with Angelique Kerber. In their first year together, they advanced to the final, primarily on the strength of the pair winning all three of their mixed doubles matches. In the final against Switzerland, Zverev lost his singles match to Federer. Although Kerber won her singles match against Belinda Bencic, they lost the decisive mixed doubles rubber. They returned in 2019 and again reached the final to set up a rematch of the previous year's final with Federer and Bencic. In a round-robin group with Australia, France, and Spain, the two of them won all six of their singles matches, but lost two of their three mixed doubles matches against Australia and France. Like the previous year, the final was decided by the mixed doubles match after Federer defeated Zverev and Kerber defeated Bencic. With the Fast4 format, the match went to three sets. In the third set tiebreak, both teams had a match point at 4–4.

Throughout the civil war, Cossacks sometimes fought as an independent ally, and other times as an auxiliary, of White armies. In South Russia, the Armed Forces of South Russia (AFSR) under General Anton Denikin relied heavily on conscripts from the Don and Kuban Cossack Hosts to fill their ranks. Through the Cossacks, the White armies acquired experienced, skilled horsemen that the Red Army was unable to match until late in the conflict. But the relationship between Cossack governments and the White leaders was frequently acrimonious. Cossack units were often ill-disciplined, and prone to bouts of looting and violence that caused the peasantry to resent the Whites. In Ukraine, Kuban and Terek Cossack squadrons carried out pogroms against Jews, despite orders from Denikin condemning such activity. Kuban Cossack politicians, wanting a semi-independent state of their own, frequently agitated against the AFSR command. In the Russian Far East, anticommunist Transbaikal and Ussuri Cossacks undermined the rear of Siberia's White armies by disrupting traffic on the Trans-Siberian Railway and engaging in acts of banditry that fueled a potent insurgency in that region. As the Red Army gained the initiative in the civil war during late 1919 and early 1920, Cossack soldiers, their families, and sometimes entire stanitsas retreated with the Whites. Some continued to fight with the Whites in the conflict's waning stages in Crimea and the Russian Far East. As many as 80,000–100,000 Cossacks eventually joined the defeated Whites in exile.

=== Prevention of Oxidative Damage === Cellular defenses against the damaging effects of oxidative stress involve both enzymatic and nonenzymatic components. The enzymatic components may directly scavenge active oxygen species or may act by producing the nonenzymatic antioxidants. There are four enzymes that provide the bulk of protection against deleterious reactions involving active oxygen in bacteria: SODs (superoxide dismutases encoded by sodA and sodB), catalases (katE and katG), glutathione synthetase (gshAB) and glutathione reductase (gor). Some bacteria have NADH-dependent peroxidases specific for H2O2. The main nonenzymatic antioxidants in E. coli are GSH and thioredoxin (encoded by trxA). Ubiquinone and menaquinone may also serve as membrane-associated antioxidants.

Sources: en.wikipedia.org

Background from the literature

== Structure and properties == Imidazole is a planar 5-membered ring, that exists in two equivalent tautomeric forms because hydrogen can be bound to one or another nitrogen atom. Imidazole is a highly polar compound, as evidenced by its electric dipole moment of 3.67 D, and is highly soluble in water. The compound is classified as aromatic due to the presence of a planar ring containing 6 π-electrons (a pair of electrons from the protonated nitrogen atom and one from each of the remaining four atoms of the ring). Some resonance structures of imidazole are shown below:

Most dietary carbohydrates contain glucose, either as their only building block (as in the polysaccharides starch and glycogen), or together with another monosaccharide (as in the hetero-polysaccharides sucrose and lactose). Unbound glucose is one of the main ingredients of honey. Glucose is extremely abundant and has been isolated from a variety of natural sources across the world, including male cones of the coniferous tree Wollemia nobilis in Rome, the roots of Ilex asprella plants in China, and straws from rice in California.

== Medical relevance == Pseudouridine exerts a subtle but significant influence on the nearby sugar-phosphate backbone and also enhances base stacking. These effects may underlie the biological role of most – but perhaps not all – of the pseudouridine residues in RNA. Certain genetic mutants lacking specific pseudouridine residues in tRNA or rRNA exhibit difficulties in translation, display slow growth rates, and fail to compete effectively with wild-type strains in mixed culture. Pseudouridine modifications are also implicated in human diseases such as mitochondrial myopathy and sideroblastic anemia (MLASA) and Dyskeratosis congenita. Dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome are two rare inherited syndromes caused by mutations in DKC1, the gene encoding for the pseudouridine synthase dyskerin. Pseudouridines have been recognized as regulators of viral latency processes in human immunodeficiency virus (HIV) infections. Pseudouridylation has also been associated with the pathogenesis of maternally inherited diabetes and deafness (MIDD). In particular, a point mutation in a mitochondrial tRNA seems to prevent the pseudouridylation of one nucleotide, thus altering the tRNA tertiary structure. This may lead to higher tRNA instability, causing deficiencies in mitochondrial translation and respiration.

The CIA has been accused of deliberately leaking classified information to undermine the 2004 election. In the election, Bush carried 31 of 50 states, receiving 286 electoral votes. He won an absolute majority of the popular vote (50.7% to Kerry's 48.3%).

Sources: en.wikipedia.org

Frequently asked questions

What is TB-500 chemically?

It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.

Where does the name come from?

The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.

Network